ArticleJACC. Case reports2025
Treating a Metastatic Pericardial Tumor.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPericardial involvement of metastatic adenocarcinoma is rare, and its treatment has historically involved several strategies. CASE SUMMARY: We describe a case of pericardial metastasis from gastrointestinal adenocarcinoma presenting with pericardial syndrome of effusive-constrictive pericarditis (ECP), managed with pericardiocentesis and drain placement followed by 10 cycles of systemic chemotherapy, leading to the resolution of pericardial disease and improved quality of life. DISCUSSION: Treatment strategies for malignant ECP in lieu of pericardiectomy have included pericardiocentesis only or pericardiocentesis with chemotherapy (either local, systemic, or both). Our approach at MD Anderson Cancer Center is to perform pericardiocentesis with temporary pericardial drain placement to decrease reaccumulation rate, followed by systemic chemotherapy to reduce pericardial tumor infiltration but limit sclerosing effect. TAKE-HOME MESSAGE: The combination of pericardiocentesis with drain placement for 3 to 5 days postpericardiocentesis followed by systemic chemotherapy can be a successful treatment strategy in ECP due to metastatic pericardial disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.